• Groundbreaking Malaria Vaccine Advancements: Saving Lives Worldwide

  • Jan 6 2025
  • Length: 3 mins
  • Podcast

Groundbreaking Malaria Vaccine Advancements: Saving Lives Worldwide

Listen for free

View show details

  • Summary

  • In the ongoing fight against malaria, significant advancements have been made, particularly in the development and implementation of malaria vaccines. Here are the latest updates from recent developments.

    Malaria continues to be a major global health challenge, with over 200 million cases and nearly half a million deaths annually, predominantly affecting young children and pregnant women in sub-Saharan Africa, Asia, and Latin America. Despite these challenges, new vaccine strategies are offering promising hope.

    Recently, a late-liver-stage attenuated malaria parasite vaccine, known as GA2, has shown high protection in a small clinical trial conducted by researchers at Leiden University Medical Center and Radboud University Medical Center in the Netherlands. This genetically modified Plasmodium falciparum parasite induced a favorable immune response and provided protective efficacy against malaria infection, marking a significant step forward in malaria vaccine development[1].

    The World Health Organization (WHO) has been at the forefront of efforts to develop an effective malaria vaccine, with a goal to achieve this by 2025. Currently, two malaria vaccines, RTS,S and R21, are recommended for use in children living in areas with moderate to high malaria transmission. These vaccines have been shown to reduce uncomplicated malaria by about 40%, severe malaria by 30%, and all-cause mortality by 13%[3][4].

    The RTS,S vaccine, developed by GlaxoSmithKline, was prequalified by the WHO in July 2022. More recently, the R21 vaccine, developed by the University of Oxford, was prequalified in December 2023. Both vaccines have demonstrated safety and efficacy in preventing malaria in children and are expected to have a high public health impact. The R21 vaccine, in particular, has shown vaccine effectiveness of up to 80% in clinical trials[4][5].

    Implementation of these vaccines is well underway. As of December 2024, 17 countries in Africa have introduced these vaccines as part of their childhood immunization programs. Additional countries are expected to follow suit in 2025. The pilot program for the RTS,S vaccine in Ghana, Kenya, and Malawi resulted in a substantial drop in mortality among children and a reduction in severe malaria hospitalizations. The Malaria Vaccine Implementation Programme (MVIP) has been completed, and these countries will continue and expand their vaccination programs with support from Gavi[4].

    Ghana and Nigeria have been pioneers in approving these new malaria vaccines for use in young children. Ghana approved the R21 vaccine in April 2023, and Nigeria followed shortly after. These approvals mark a significant milestone in the fight against malaria, with the potential to save tens of thousands of young lives each year[5].

    In summary, the recent developments in malaria vaccines, including the promising GA2 vaccine and the widespread implementation of RTS,S and R21 vaccines, offer new hope in the battle against this devastating disease. With continued support and rollout, these vaccines are poised to make a significant impact on malaria mortality and contribute to the long-term goal of malaria eradication.
    Show More Show Less
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Groundbreaking Malaria Vaccine Advancements: Saving Lives Worldwide

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available